LLY

1,016.59

+3.31%↑

JNJ

209.48

+3.79%↑

ABBV

224.47

+1.31%↑

UNH

331.77

+2.86%↑

AZN

91.18

+0.61%↑

LLY

1,016.59

+3.31%↑

JNJ

209.48

+3.79%↑

ABBV

224.47

+1.31%↑

UNH

331.77

+2.86%↑

AZN

91.18

+0.61%↑

LLY

1,016.59

+3.31%↑

JNJ

209.48

+3.79%↑

ABBV

224.47

+1.31%↑

UNH

331.77

+2.86%↑

AZN

91.18

+0.61%↑

LLY

1,016.59

+3.31%↑

JNJ

209.48

+3.79%↑

ABBV

224.47

+1.31%↑

UNH

331.77

+2.86%↑

AZN

91.18

+0.61%↑

LLY

1,016.59

+3.31%↑

JNJ

209.48

+3.79%↑

ABBV

224.47

+1.31%↑

UNH

331.77

+2.86%↑

AZN

91.18

+0.61%↑

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

195.13 2.87

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

187.7

Massimo

196.26

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

P/E

Media del settore

592.3

77.671

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-1.21% downside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

407M

9.2B

Apertura precedente

192.26

Chiusura precedente

195.13

Notizie sul Sentiment di mercato

By Acuity

50%

50%

195 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 dic 2025, 22:02 UTC

Utili

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Utili

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Discorsi di Mercato

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Utili

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Discorsi di Mercato

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Utili

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Utili

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

-1.21% in calo

Previsioni per 12 mesi

Media 192.5 USD  -1.21%

Alto 225 USD

Basso 165 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

6

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

195 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat